Literature DB >> 24789435

Prognostic factors for desmoid tumor: a surgical series of 233 patients at a single institution.

Wei-Gen Zeng1, Zhi-Xiang Zhou, Jian-Wei Liang, Hui-Rong Hou, Zheng Wang, Hai-Tao Zhou, Xing-Mao Zhang, Jun-Jie Hu.   

Abstract

Desmoid tumors are rare soft tissue tumors with limited data on their management and prognosis. We sought to determine the rates of recurrence after surgery for desmoid tumors and analyze factors predictive of recurrence-free survival (RFS). From February 1976 to October 2011, 233 consecutive patients with desmoid tumors who underwent macroscopically complete resection were included in this study. Clinicopathologic and treatment characteristics were evaluated to determine predictors of recurrence. Patterns of presentation included primary (n = 156, 67.0 %) and locally recurrent (n = 77, 33.0 %) disease initially treated elsewhere. Most patients had a R0 resection (n = 169, 72.5 %). In addition to surgery, 43 (18.5 %) patients received radiotherapy and 10 (4.3 %) patients received systemic therapy. Median follow-up was 54 months; recurrence disease was observed in 62 (26.6 %) patients. The estimated 5- and 10-year RFS was 74.2 % (95 % confidence interval (CI), 68.3-80.1) and 70.7 % (95 % CI, 64.2-77.2), respectively. Factors associated with worse RFS were tumor size larger than 5 cm (hazard ratio (HR) = 3.757; 95 % CI, 1.945-7.259; p < 0.001), extra-abdominal tumor location (abdominal wall referent; HR = 3.373; 95 % CI, 1.425-7.984; p = 0.006), and R1 resection status (HR = 1.901; 95 % CI, 1.140-3.171; p = 0.014). Patients were grouped according to the number of unfavorable prognostic factors; the 10-year RFS rates of patients with zero, one, two, and three prognostic factors were 100, 86.9, 48.5, and 34.4 %, respectively (p < 0.001). Regardless of primary or recurrent disease, surgical resection remains central to the management of patients with desmoid tumors. However, there are clearly different prognostic subgroups that could benefit from different therapeutic strategies, and a wait-and-see policy is a possible option for a subset of patients.

Entities:  

Mesh:

Year:  2014        PMID: 24789435     DOI: 10.1007/s13277-014-2002-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  37 in total

1.  Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national Patterns of Care Study.

Authors:  Oliver Micke; M Heinrich Seegenschmiedt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-01       Impact factor: 7.038

2.  Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients.

Authors:  Peter D Peng; Omar Hyder; Michael N Mavros; Ryan Turley; Ryan Groeschl; Amin Firoozmand; Michael Lidsky; Joseph M Herman; Michael Choti; Nita Ahuja; Robert Anders; Daniel G Blazer; T Clark Gamblin; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2012-09-13       Impact factor: 5.344

3.  Aggressive fibromatosis of the abdominal wall, limbs and limb girdles.

Authors:  S R Phillips; R A'Hern; J M Thomas
Journal:  Br J Surg       Date:  2004-12       Impact factor: 6.939

4.  Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution.

Authors:  A Gronchi; P G Casali; L Mariani; S Lo Vullo; M Colecchia; L Lozza; R Bertulli; M Fiore; P Olmi; M Santinami; J Rosai
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

5.  Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation.

Authors:  Sébastien Salas; Armelle Dufresne; Binh Bui; Jean-Yves Blay; Philippe Terrier; Dominique Ranchere-Vince; Sylvie Bonvalot; Eberhard Stoeckle; Louis Guillou; Axel Le Cesne; Odile Oberlin; Véronique Brouste; Jean-Michel Coindre
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

6.  Aggressive fibromatosis (non-familial desmoid tumour): therapeutic problems and the role of adjuvant radiotherapy.

Authors:  J T Plukker; I van Oort; A Vermey; I Molenaar; H J Hoekstra; A K Panders; W V Dolsma; H S Koops
Journal:  Br J Surg       Date:  1995-04       Impact factor: 6.939

7.  A prognostic nomogram for prediction of recurrence in desmoid fibromatosis.

Authors:  Aimeé M Crago; Brian Denton; Sébastien Salas; Armelle Dufresne; James J Mezhir; Meera Hameed; Mithat Gonen; Samuel Singer; Murray F Brennan
Journal:  Ann Surg       Date:  2013-08       Impact factor: 12.969

8.  Management of desmoid tumors.

Authors:  J G McKinnon; J P Neifeld; S Kay; G A Parker; W C Foster; W Lawrence
Journal:  Surg Gynecol Obstet       Date:  1989-08

9.  Desmoid tumors of the trunk and extremity.

Authors:  C P Karakousis; J Mayordomo; G C Zografos; D L Driscoll
Journal:  Cancer       Date:  1993-09-01       Impact factor: 6.860

10.  Extra-abdominal desmoid tumours: a review of the literature.

Authors:  A P Molloy; B Hutchinson; G C O'Toole
Journal:  Sarcoma       Date:  2012-08-16
View more
  10 in total

1.  Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients.

Authors:  Daniel Robert Quast; Ralph Schneider; Emanuel Burdzik; Steffen Hoppe; Gabriela Möslein
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

2.  Large desmoid-type fibromatosis of the shoulder girdle: operative approach selection and clinic outcome.

Authors:  Fan Tang; Li Min; Rui Yin; Wenli Zhang; Yong Zhou; Yi Luo; Rui Shi; Hong Duan; Chongqi Tu
Journal:  Int Orthop       Date:  2015-01-21       Impact factor: 3.075

3.  Peutz-Jeghers syndrome with mesenteric fibromatosis: A case report and review of literature.

Authors:  Huai-Jie Cai; Han Wang; Nan Cao; Wei Wang; Xi-Xi Sun; Bin Huang
Journal:  World J Clin Cases       Date:  2020-02-06       Impact factor: 1.337

4.  Efficacy of vinorelbine combined with low-dose methotrexate for treatment of inoperable desmoid tumor and prognostic factor analysis.

Authors:  Shu Li; Zhengfu Fan; Zhiwei Fang; Jiayong Liu; Chujie Bai; Ruifeng Xue; Lu Zhang; Tian Gao
Journal:  Chin J Cancer Res       Date:  2017-10       Impact factor: 5.087

5.  [Long-term effectiveness of "West China Classification" guided surgical treatment of desmoid-type fibromatosis in shoulder girdle].

Authors:  Sisi Zhou; Fan Tang; Li Min; Yi Luo; Yong Zhou; Hong Duan; Chongqi Tu
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-06-15

6.  Primary asymptomatic desmoid tumor of the mesentery.

Authors:  George Ap Efthimiopoulos; Dimitrios Chatzifotiou; Maria Drogouti; George Zafiriou
Journal:  Am J Case Rep       Date:  2015-03-17

7.  Outcome of surgery for primary and recurrent desmoid-type fibromatosis. A retrospective case series of 174 patients.

Authors:  Panagiotis Tsagozis; Jonathan Daniel Stevenson; Robert Grimer; Simon Carter
Journal:  Ann Med Surg (Lond)       Date:  2017-03-22

8.  Four different treatment strategies in aggressive fibromatosis: A systematic review.

Authors:  Jojanneke M Seinen; Maarten G Niebling; Esther Bastiaannet; Betty Pras; Harald J Hoekstra
Journal:  Clin Transl Radiat Oncol       Date:  2018-03-06

9.  Factors Associated with Disease Stabilization of Desmoid-Type Fibromatosis.

Authors:  Yongsung Kim; Mamer S Rosario; Hwan Seong Cho; Ilkyu Han
Journal:  Clin Orthop Surg       Date:  2020-02-13

10.  Successful treatment of giant mesenteric fibromatosis with surgery and tamoxifen: case report.

Authors:  Zhixiang Jin; Qi Zhang; Dong Tang; Liuhua Wang; Wei Wang; Minghao Xu; Zhi Li; Daorong Wang
Journal:  Transl Cancer Res       Date:  2019-06       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.